Newsletter
News and Events
Home
Company
Pipeline
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
© relief therapeutics 2024
Latest News
Stay up to date on Relief activities
Corporate News
Archive
Relief Therapeutics has published its Annual Report
30 April 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
27 March 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
22 March 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
28 February 2024 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
5 December 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces CEO Transition
22 November 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
10 October 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
15 September 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
30 August 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
23 June 2023 |
Ad Hoc Announcement pursuant to Art. 53 LR
Company
Pipeline
Investor Relations
News and Events
© Relief Therapeutics